A Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CML

NCT02973711 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped lack of funding

Conditions

Leukemia, Chronic Myeloid

Interventions

DRUG: Nilotinib
DRUG: Ruxolitinib

Sponsor

University of Michigan Rogel Cancer Center